Preferred Label : Surovatamig;
NCIt synonyms : Anti-CD19/CD3 T-cell Engaging Bispecific Antibody TNB-486; Anti-CD19/CD3 T-cell Engaging Bispecific Antibody AZD0486; CD19 x CD3 Bispecific Antibody AZD0486; CD19/CD3 T-cell Engager AZD0486; TCE AZD0486; Anti-CD19/CD3 Bispecific Antibody AZD0486;
NCIt definition : A human bispecific T-cell engager antibody composed of a fixed-light-chain (FLC) arm
targeting the CD3 antigen found on T-lymphocytes and a heavy-chain-only (HCO) arm
targeting the B-cell-specific membrane protein CD19, with potential immunostimulating
and antineoplastic activities. Upon administration, surovatamig binds to both the
CD3 antigen on cytotoxic T-lymphocytes (CTLs) and the CD19 antigen expressed on malignant
B-cells. This activates and redirects CTLs to CD19-expressing tumor cells, resulting
in CTL-mediated killing of tumor cells. CD19 is a membrane antigen that is widely
expressed during B-cell development, from pro-B-cell to early plasma cell stages.
The FLC arm weakly activates CD3. The HCO arm has a high affinity anti-CD19 moiety.;
UNII : 3QW12I37H1;
CAS number : 2892667-02-4;
Molecule name : TNB-486; TNB 486; AZD-0486; AZD 0486;
NCI Metathesaurus CUI : CL1648067;
Origin ID : C178577;
UMLS CUI : C5555141;
Semantic type(s)
- chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
